Key facts
- DT Axis’s last known valuation is $60.8M (Mar 2022).
- It has raised $10.9M; the latest was Later Stage VC in Dec 2025.
- Notable investors include Mitsubishi UFJ Capital, Development Bank of Japan, Axil Capital Partners, Himawari Pharmaceutical, Mitsubishi Tanabe Pharma.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for DT Axis
- ·The full record, as it builds
Funding rounds
No funding rounds for DT Axis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DT Axis
Developer of a medical platform designed for treating depression based on cognitive behavior therapy. The company engages in promoting research and development and sales in the medical device field using the application and is intended to develop new digital treatments for depression, enabling health professionals to treat mental illness.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2020
- Employees
- 10
- Website
- dt-axis.co.jp/
- Ownership
- Privately Held (backing)
DT Axis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DT Axis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DT Axis in its N-PORT filings yet. We sweep new filings monthly.